[
  {
    "ts": null,
    "headline": "C3 AI Announces Fiscal Second Quarter 2026 Results",
    "summary": "REDWOOD CITY, Calif., December 03, 2025--C3.ai, Inc. (\"C3 AI,\" \"C3,\" or the \"Company\") (NYSE: AI), the Enterprise AI application software company, today announced financial results for its fiscal second quarter ended October 31, 2025.",
    "url": "https://finnhub.io/api/news?id=409dbba8ffd05183e7f1586f65eaab5b6bef7f0efd5273e4be227bed8295ad17",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1764795900,
      "headline": "C3 AI Announces Fiscal Second Quarter 2026 Results",
      "id": 137677816,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "BMY",
      "source": "Yahoo",
      "summary": "REDWOOD CITY, Calif., December 03, 2025--C3.ai, Inc. (\"C3 AI,\" \"C3,\" or the \"Company\") (NYSE: AI), the Enterprise AI application software company, today announced financial results for its fiscal second quarter ended October 31, 2025.",
      "url": "https://finnhub.io/api/news?id=409dbba8ffd05183e7f1586f65eaab5b6bef7f0efd5273e4be227bed8295ad17"
    }
  },
  {
    "ts": null,
    "headline": "Sector Update: Health Care Stocks Higher Late Afternoon",
    "summary": "Health care stocks rose late Wednesday afternoon, with the NYSE Health Care Index up 0.5% and the He",
    "url": "https://finnhub.io/api/news?id=d7a84725d89445c90d7228242101b93b9632e4861d7a4f88ad8045728c7c8baf",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1764795023,
      "headline": "Sector Update: Health Care Stocks Higher Late Afternoon",
      "id": 137678030,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "BMY",
      "source": "Yahoo",
      "summary": "Health care stocks rose late Wednesday afternoon, with the NYSE Health Care Index up 0.5% and the He",
      "url": "https://finnhub.io/api/news?id=d7a84725d89445c90d7228242101b93b9632e4861d7a4f88ad8045728c7c8baf"
    }
  },
  {
    "ts": null,
    "headline": "Sector Update: Health Care Stocks Higher Wednesday Afternoon",
    "summary": "Health care stocks rose Wednesday afternoon, with the NYSE Health Care Index and the Health Care Sel",
    "url": "https://finnhub.io/api/news?id=6ed6845038f0231f0f629ac32bb4fc9787623d5abf0312e67d297315a4ce51b6",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1764786953,
      "headline": "Sector Update: Health Care Stocks Higher Wednesday Afternoon",
      "id": 137678033,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "BMY",
      "source": "Yahoo",
      "summary": "Health care stocks rose Wednesday afternoon, with the NYSE Health Care Index and the Health Care Sel",
      "url": "https://finnhub.io/api/news?id=6ed6845038f0231f0f629ac32bb4fc9787623d5abf0312e67d297315a4ce51b6"
    }
  },
  {
    "ts": null,
    "headline": "Health Care Up on Alzheimer's Hopes - Health Care Roundup",
    "summary": "Health Care Up on Alzheimer's Hopes - Health Care Roundup",
    "url": "https://finnhub.io/api/news?id=c8b91448ba19dde0991554580744db5195a525833d89c3e267af1097947e7644",
    "source": "MarketWatch",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1764782460,
      "headline": "Health Care Up on Alzheimer's Hopes - Health Care Roundup",
      "id": 137685460,
      "image": "",
      "related": "BMY",
      "source": "MarketWatch",
      "summary": "Health Care Up on Alzheimer's Hopes - Health Care Roundup",
      "url": "https://finnhub.io/api/news?id=c8b91448ba19dde0991554580744db5195a525833d89c3e267af1097947e7644"
    }
  },
  {
    "ts": null,
    "headline": "Why Is Sarepta Therapeutics (SRPT) Up 26.4% Since Last Earnings Report?",
    "summary": "Sarepta Therapeutics (SRPT) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.",
    "url": "https://finnhub.io/api/news?id=ad4e27632a95148d07aba4d67dfcbc8fd405aa31f8ec1401bc6eab80f74f603e",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1764779416,
      "headline": "Why Is Sarepta Therapeutics (SRPT) Up 26.4% Since Last Earnings Report?",
      "id": 137678078,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "BMY",
      "source": "Yahoo",
      "summary": "Sarepta Therapeutics (SRPT) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.",
      "url": "https://finnhub.io/api/news?id=ad4e27632a95148d07aba4d67dfcbc8fd405aa31f8ec1401bc6eab80f74f603e"
    }
  },
  {
    "ts": null,
    "headline": "Why A Surprise Delay For Cobenfy Just Sparked Bristol Myers Stock",
    "summary": "Why A Surprise Delay For Cobenfy Just Sparked Bristol Myers Stock",
    "url": "https://finnhub.io/api/news?id=2c4cd50e4e5a4faad40e751a80a803c3355b759a231d03f744c025078aa7fa17",
    "source": "DowJones",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1764778243,
      "headline": "Why A Surprise Delay For Cobenfy Just Sparked Bristol Myers Stock",
      "id": 137685440,
      "image": "",
      "related": "BMY",
      "source": "DowJones",
      "summary": "Why A Surprise Delay For Cobenfy Just Sparked Bristol Myers Stock",
      "url": "https://finnhub.io/api/news?id=2c4cd50e4e5a4faad40e751a80a803c3355b759a231d03f744c025078aa7fa17"
    }
  },
  {
    "ts": null,
    "headline": "Bristol-Myers Stock Rises on Alzheimer’s Drug Study Update",
    "summary": "Bristol-Myers Squibb shares rallied Wednesday after the drugmaker delayed the release of eagerly awaited clinical-trial results for a potential Alzheimer’s disease treatment.  Analysts said investors were relieved that the news wasn’t worse, as there had been some fear that Bristol-Myers would disclose by the end of this month that the study failed outright.  The study is testing Bristol-Myers’ Cobenfy schizophrenia drug as a treatment for psychosis in Alzheimer’s disease patients.",
    "url": "https://finnhub.io/api/news?id=80c93e9413ec173547003c4ff8dc891689c9aad7e2796f62fa1242e476b6ddd5",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1764777886,
      "headline": "Bristol-Myers Stock Rises on Alzheimer’s Drug Study Update",
      "id": 137672858,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "BMY",
      "source": "Yahoo",
      "summary": "Bristol-Myers Squibb shares rallied Wednesday after the drugmaker delayed the release of eagerly awaited clinical-trial results for a potential Alzheimer’s disease treatment.  Analysts said investors were relieved that the news wasn’t worse, as there had been some fear that Bristol-Myers would disclose by the end of this month that the study failed outright.  The study is testing Bristol-Myers’ Cobenfy schizophrenia drug as a treatment for psychosis in Alzheimer’s disease patients.",
      "url": "https://finnhub.io/api/news?id=80c93e9413ec173547003c4ff8dc891689c9aad7e2796f62fa1242e476b6ddd5"
    }
  },
  {
    "ts": null,
    "headline": "Terray Therapeutics Achieves AI-Enabled Drug Discovery Milestone in Collaboration with Bristol Myers Squibb",
    "summary": "LOS ANGELES, December 03, 2025--Terray Reaches Milestone in Collaboration with Bristol Myers Squibb",
    "url": "https://finnhub.io/api/news?id=d47b8dd3a4f1f5640a2a5fd6637c2004c7c3f5dbdd892c7b5f378737573e9f07",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1764777600,
      "headline": "Terray Therapeutics Achieves AI-Enabled Drug Discovery Milestone in Collaboration with Bristol Myers Squibb",
      "id": 137672859,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "BMY",
      "source": "Yahoo",
      "summary": "LOS ANGELES, December 03, 2025--Terray Reaches Milestone in Collaboration with Bristol Myers Squibb",
      "url": "https://finnhub.io/api/news?id=d47b8dd3a4f1f5640a2a5fd6637c2004c7c3f5dbdd892c7b5f378737573e9f07"
    }
  },
  {
    "ts": null,
    "headline": "Shares of Bristol Myers Squibb rise despite delay in clinical trial of promising drug",
    "summary": "Shares of Bristol Myers Squibb rise despite delay in clinical trial of promising drug",
    "url": "https://finnhub.io/api/news?id=578e3376ce44d841d25234ce19f9d5f77b3f23ddb614891c222596fb25f220c2",
    "source": "MarketWatch",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1764772411,
      "headline": "Shares of Bristol Myers Squibb rise despite delay in clinical trial of promising drug",
      "id": 137685461,
      "image": "",
      "related": "BMY",
      "source": "MarketWatch",
      "summary": "Shares of Bristol Myers Squibb rise despite delay in clinical trial of promising drug",
      "url": "https://finnhub.io/api/news?id=578e3376ce44d841d25234ce19f9d5f77b3f23ddb614891c222596fb25f220c2"
    }
  },
  {
    "ts": null,
    "headline": "Bristol Myers Squibb Stock Climbs on Alzheimer’s Trial Update. What to Know.",
    "summary": "The drugmaker is testing its antipsychotic drug Cobenfy for the treatment of psychosis associated with Alzheimer’s disease.",
    "url": "https://finnhub.io/api/news?id=8ff5f981d3476b35e754c434f75e5fcf803f5c2b903a34939317db80e6dcd7fe",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1764771360,
      "headline": "Bristol Myers Squibb Stock Climbs on Alzheimer’s Trial Update. What to Know.",
      "id": 137671260,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "BMY",
      "source": "Yahoo",
      "summary": "The drugmaker is testing its antipsychotic drug Cobenfy for the treatment of psychosis associated with Alzheimer’s disease.",
      "url": "https://finnhub.io/api/news?id=8ff5f981d3476b35e754c434f75e5fcf803f5c2b903a34939317db80e6dcd7fe"
    }
  },
  {
    "ts": null,
    "headline": "A delayed clinical trial actually boosted Bristol Myers Squibb’s stock. Here’s why.",
    "summary": "A delayed clinical trial actually boosted Bristol Myers Squibb’s stock. Here’s why.",
    "url": "https://finnhub.io/api/news?id=da2645389102b3e6922fac291cbc92a6eea8e18e5fb647a60a3eba05db8cf32d",
    "source": "MarketWatch",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1764770700,
      "headline": "A delayed clinical trial actually boosted Bristol Myers Squibb’s stock. Here’s why.",
      "id": 137685462,
      "image": "",
      "related": "BMY",
      "source": "MarketWatch",
      "summary": "A delayed clinical trial actually boosted Bristol Myers Squibb’s stock. Here’s why.",
      "url": "https://finnhub.io/api/news?id=da2645389102b3e6922fac291cbc92a6eea8e18e5fb647a60a3eba05db8cf32d"
    }
  },
  {
    "ts": null,
    "headline": "Bristol Myers Squibb Company (BMY) Is a Trending Stock: Facts to Know Before Betting on It",
    "summary": "Recently, Zacks.com users have been paying close attention to Bristol Myers (BMY). This makes it worthwhile to examine what the stock has in store.",
    "url": "https://finnhub.io/api/news?id=8952dc487f018ac3d2bbeecc399c4f8e993143b117e48b2fb64777bb45f256b6",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1764770403,
      "headline": "Bristol Myers Squibb Company (BMY) Is a Trending Stock: Facts to Know Before Betting on It",
      "id": 137671262,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "BMY",
      "source": "Yahoo",
      "summary": "Recently, Zacks.com users have been paying close attention to Bristol Myers (BMY). This makes it worthwhile to examine what the stock has in store.",
      "url": "https://finnhub.io/api/news?id=8952dc487f018ac3d2bbeecc399c4f8e993143b117e48b2fb64777bb45f256b6"
    }
  },
  {
    "ts": null,
    "headline": "After finding ‘irregularities,’ Bristol Myers to extend key trial of Cobenfy in Alzheimer’s psychosis",
    "summary": "Data from the \"ADEPT-2\" study, which analysts had hoped would arrive before year's end, are now expected sometime in 2026.",
    "url": "https://finnhub.io/api/news?id=40a8acc92ec96a23623a9b4f1882476ea5f2d31a6bd47d3e9482012662ddc1ce",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1764763320,
      "headline": "After finding ‘irregularities,’ Bristol Myers to extend key trial of Cobenfy in Alzheimer’s psychosis",
      "id": 137672861,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "BMY",
      "source": "Yahoo",
      "summary": "Data from the \"ADEPT-2\" study, which analysts had hoped would arrive before year's end, are now expected sometime in 2026.",
      "url": "https://finnhub.io/api/news?id=40a8acc92ec96a23623a9b4f1882476ea5f2d31a6bd47d3e9482012662ddc1ce"
    }
  },
  {
    "ts": null,
    "headline": "Bristol Myers Squibb Announces Continuation of ADEPT-2 Phase 3 Study in Psychosis Associated with Alzheimer's Disease",
    "summary": "PRINCETON, N.J., December 03, 2025--Bristol Myers Squibb Announces Continuation of ADEPT-2 Phase 3 Study in Psychosis Associated with Alzheimer's Disease",
    "url": "https://finnhub.io/api/news?id=57f3a363ab945516eec627176c743c78ecededa87285b08b0b69343ccdccd9e4",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1764763140,
      "headline": "Bristol Myers Squibb Announces Continuation of ADEPT-2 Phase 3 Study in Psychosis Associated with Alzheimer's Disease",
      "id": 137671263,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "BMY",
      "source": "Yahoo",
      "summary": "PRINCETON, N.J., December 03, 2025--Bristol Myers Squibb Announces Continuation of ADEPT-2 Phase 3 Study in Psychosis Associated with Alzheimer's Disease",
      "url": "https://finnhub.io/api/news?id=57f3a363ab945516eec627176c743c78ecededa87285b08b0b69343ccdccd9e4"
    }
  },
  {
    "ts": null,
    "headline": "Cantor Fitzgerald Maintains Price Target on Bristol-Myers (BMY) Amid Milvexian Updates",
    "summary": "Bristol-Myers Squibb Company (NYSE:BMY) ranks among the Best Low Volatility Investments in December 2025. Cantor Fitzgerald reaffirmed its Neutral rating and $45 price target on Bristol-Myers Squibb Company (NYSE:BMY) on November 24. Recent data, according to the firm, offers “tangible evidence that FXIa inhibition can blunt thrombosis while sparing hemostasis,” which bolsters trust in BMY’S […]",
    "url": "https://finnhub.io/api/news?id=ff06c15560828528cfe60e6fd62168f4c86b4ece0fb148f5c0d4c2f2fb6eebff",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1764745063,
      "headline": "Cantor Fitzgerald Maintains Price Target on Bristol-Myers (BMY) Amid Milvexian Updates",
      "id": 137667976,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "BMY",
      "source": "Yahoo",
      "summary": "Bristol-Myers Squibb Company (NYSE:BMY) ranks among the Best Low Volatility Investments in December 2025. Cantor Fitzgerald reaffirmed its Neutral rating and $45 price target on Bristol-Myers Squibb Company (NYSE:BMY) on November 24. Recent data, according to the firm, offers “tangible evidence that FXIa inhibition can blunt thrombosis while sparing hemostasis,” which bolsters trust in BMY’S […]",
      "url": "https://finnhub.io/api/news?id=ff06c15560828528cfe60e6fd62168f4c86b4ece0fb148f5c0d4c2f2fb6eebff"
    }
  },
  {
    "ts": null,
    "headline": "Goldman Sachs Maintains Bristol-Myers Squibb (BMY) Neutral Recommendation",
    "summary": "Goldman Sachs Maintains Bristol-Myers Squibb (BMY) Neutral Recommendation",
    "url": "https://finnhub.io/api/news?id=b8001e502ee43aee35dcb95ea0130c36c2965f5851265f53e4ff031064eeeca1",
    "source": "Fintel",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1764720289,
      "headline": "Goldman Sachs Maintains Bristol-Myers Squibb (BMY) Neutral Recommendation",
      "id": 137665462,
      "image": "",
      "related": "BMY",
      "source": "Fintel",
      "summary": "",
      "url": "https://finnhub.io/api/news?id=b8001e502ee43aee35dcb95ea0130c36c2965f5851265f53e4ff031064eeeca1"
    }
  }
]